Ultrahuman: $70M from Qualcomm to turn smart rings from trackers into computers

Ultrahuman, founded in Bengaluru in 2019 by Mohit Kumar and Vatsal Singhal, sells health wearables — the Ring Air and Ring Pro smart rings — plus continuous glucose monitors, blood biomarker testing and environmental sensing. It frames itself as a human-computer interface company: its Jade AI system combines wearable, biochemical and environmental signals into health intelligence, and about 12% of users pay for PowerPlugs, its subscription software layer. A Qualcomm-powered ring designed to run software directly on-device is in development.

That a ring can become a personal computer: Qualcomm-powered hardware plus on-device software so programs, games and AI run on the finger, not the phone or cloud.

$70M announced September 4, 2026, led by Qualcomm Ventures per Moneycontrol, with Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital also investing; TechCrunch reports $65M in primary equity plus $5M in debt at a $365M valuation, about three times the $120M valuation of 2023.

Co-founded in Bengaluru in 2019 by Mohit Kumar and Vatsal Singhal, Ultrahuman launched with continuous glucose monitors for metabolic health before moving into smart rings, which became its mainstay, and later added blood testing and environmental sensing. A US patent dispute with rival Oura forced the company to stop selling its Ring Air in the US for much of the past year; it returned with a redesigned Ring Pro in 2026.

Ultrahuman's existing business was already scaling when it made the platform bet public: an annual revenue run rate of $140M, about 800,000 rings sold, and 12% of users paying for PowerPlugs. On September 4, 2026 it announced a $70M round backed by Qualcomm Ventures, Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital, and said it is working with Qualcomm on a new ring using the chipmaker's silicon. Computer-style features — game-controller mode, AI interactions and third-party developer access — are due on existing Ring Air and Ring Pro devices through a software update by the end of September 2026.

Still scaling as of September 2026: Ultrahuman expects its revenue run rate to reach $200M by January 2027 and aims to triple US volumes over the following four quarters as supply ramps; it says it may not be profitable in 2026 after spending on physical stores, brand and clinical research, with an IPO unlikely before 2028. The Qualcomm-powered ring is planned for later, so the computer-on-a-finger thesis is being tested first through software updates on today's rings.

Position matters: as long as the product is a health tracker, competition is sensor-by-sensor against Oura and Samsung; reframing it as a computer opens software, games and a developer platform.

The finger is a defensible location: a ring can be a precise pointer, controller or AI interface while carrying heart-rate, temperature and movement context no watch matches.

A chip partner is the unlock: Qualcomm brings the low-power silicon and ecosystem needed to run software on a finger-sized device, turning a hardware bet into a platform bet.

The health data widens the moat: Labcorp and Pulsomics research tie longitudinal wearable signals to blood biomarkers, so each ring sold feeds models that make the next ring harder to beat.

Renaming the device changes what you can build on it: Ultrahuman stopped adding sensors to a health tracker and started opening the ring to software, games and third-party developers.

As of September 4, 2026 Ultrahuman was deploying its $70M round to build the ring-as-computer: a Qualcomm-powered ring in development, and software features such as game-controller mode, AI interaction and third-party developer access arriving on existing rings by the end of September 2026. It reported a $140M revenue run rate, 800,000 rings sold and a $200M run-rate target for January 2027, while saying it may not be profitable in 2026 and that an IPO is unlikely before 2028. Whether users treat the ring as a computing platform rather than a health gadget was still being tested.